Opinion

Video

Exploring Treatments for BCG-Unresponsive Intermediate-High Risk NMIBC

Expert urologist explores potential treatments for BCG-unresponsive intermediate and high-risk non-muscle-invasive bladder cancer (NMIBC), including immune checkpoint inhibitors, oncolytic viral therapy, cytokine agonists, immunomodulators, and the recently approved drugs pembrolizumab and nogapendekin alfa inbakicept-pmln.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      1. Can you discuss some of the exploratory treatments for BCG‐unresponsive intermediate and high risk‐NMIBC? (eg. immune checkpoint inhibitors (ICI), oncolytic viral therapy, cytokine agonists, and other immunomodulators)
      2. BCG‐unresponsiveness (definition?)
        1. Include (recently) approved immunotherapies: pembrolizumab, nogapendekin alfa inbakicept-pmln
      3. Gene therapy: nadofaragene firadenovec
      Related Videos
      Laura Davis, MD, on link between microplastics and bladder cancer
      Laura Davis, MD, on link between microplastics and bladder cancer
      NMIBC Maintenance Therapy: Timing, Dosing, and Follow-Up
      NMIBC Maintenance Therapy: Timing, Dosing, and Follow-Up
      1 expert is featured in this series.
      BRCA Mutations in mHSPC: Impact on Therapy Selection
      1 expert is featured in this series.
      Formulations, Food, and Frequency: Optimizing Absorption and Tolerability in Daily Practice
      Defining and Managing BCG-Unresponsive NMIBC
      Defining and Managing BCG-Unresponsive NMIBC
      1 expert is featured in this series.
      Factors Contributing to Higher Incidence and Worse Outcomes of mHSPC in Black Men
      1 expert is featured in this series.
      The Incidence of Prostate Cancer and Risk of Progression in Black Men
      2 experts are featured in this series.
      The Biggest Challenges in Distinguishing ccRCC From Benign Renal Masses
      2 experts are featured in this series.
      The Evolvement of Imaging in ccRCC
      Rebecca A. Campbell, MD, answers a question during a Zoom video interview
      Rebecca A. Campbell, MD, discusses citation rates for men and women in the oncology literature
      Related Content
      Woman talking with a doctor online using digital tablet | Image Credit: © rh2010 - stock.adobe.com
      May 15th 2025

      Telehealth in urologic cancer: Lessons learned from the COVID-19 pandemic

      Tracey L. Krupski, MD Jeunice Owens-Walton, MD
      "The use of telemedicine is heavily dependent on supportive legislature," write Tracey L. Krupski, MD, and Jeunice Owens-Walton, MD.
      Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25
      May 4th 2025

      Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25

      Amy M. Pearlman, MD Kevin C. Zorn, MD, FRCSC, FACS
      Urologists discuss innovative BPH treatments, emphasizing personalized care, and the importance of ejaculatory preservation.
      Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
      May 9th 2025

      Durvalumab plus BCG significantly improves DFS in NMIBC

      Benjamin P. Saylor Hannah Clarke
      The data are to be presented at an upcoming medical conference.
      Pearls & Perspectives: Understanding and addressing priapism, with Serge Carrier, MD, and Gregory Broderick, MD
      May 2nd 2025

      Pearls & Perspectives: Understanding and addressing priapism, with Serge Carrier, MD, and Gregory Broderick, MD

      Amy M. Pearlman, MD
      Experts discuss urgent priapism management strategies, emphasizing timely intervention and collaboration for optimal patient outcomes.
      FDA to host advisory committee meeting on UGN-102 for NMIBC
      May 7th 2025

      FDA to host advisory committee meeting on UGN-102 for NMIBC

      Hannah Clarke
      The Oncologic Drugs Advisory Committee meeting is scheduled for May 21, 2025.
      FDA issues refusal to file letter on sBLA for nogapendekin alfa inbakicept
      May 5th 2025

      FDA issues refusal to file letter on sBLA for nogapendekin alfa inbakicept

      Hannah Clarke
      The sBLA for NAI was submitted to the FDA in March 2025.
      © 2025 MJH Life Sciences

      All rights reserved.